Diffuse cutaneous systemic sclerosis ("dcSSc") is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including ...
Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...
Initial $50M Series A investment from founding investor RTW InvestmentsProceeds will fund clinical development of PRO-203 in systemic sclerosis ...
The prevalence of SSc among Alaska Native and American Indian adults is comparable to or higher than other populations, with high GI and pulmonary involvement.
Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other systemic complications.
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating ...
A retrospective cohort study found that beta-blocker use is associated with a decreased risk for incident HF in certain SAID populations.
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Proximal weakness and elevated creatine kinase were ...
A nationwide Swedish register-based study revealed that individuals with systemic sclerosis had a higher risk for hematologic malignancies. Myeloid malignancies typically presented around disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results